The Surprising FDA View That Sent Moderna Stock Flying

Moderna (MRNA) stock surged Tuesday after documents posted ahead of a key meeting suggested the Food and Drug Administration would likely approve the company's mRNA-based flu shot. The FDA posted the briefing documents ahead of the Vaccines and Related Biological Products Advisory Committee meeting slated for Aug. 5. Advisors will debate and make recommendations on the benefits and risks of…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related news

Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine

10/26/2026 Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.

10/26/2026 Moderna stock yo-yoed Monday on more muted expectations for its...

Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?

Dow Jones Futures Fall After Moderna Crashes, Meta Fuels AI Meltdown. Warren Buffett Market Is Thriving.

Merck, Moderna Unveil Cancer Vaccine Data — After A Leak Stole Their Thunder

Dow Jones Futures Fall, Yields Jump After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Twilio To Join S&P 500 Index

After Moderna's 'Outsized Run,' It May Be Time For This Bearish Move

Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz